Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-33092 LEMAITRE VASCULAR, INC. (Exact name of registrant as specified in its charter) Delaware 04-2825458 (Sta ...

Investors might want to bet on LeMaitre Vascular (LMAT) , as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change. The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate. The power of a ...

LeMaitre Vascular, Inc. (NASDAQ:LMAT) Q2 2024 Results Conference Call August 1, 2024 5:00 PM ET Company Participants J.J. Pellegrino - Chief Financial Officer George LeMaitre - Chief Executive Officer Dave Roberts - President Conference Call Participants Rick Wise - Stifel Jason Wittes - ROTH Danny Stauder - Citizens JMP Michael Sarcone - Jefferies Michael Petusky - Barrington Research Frank Takkinen - Lake Street Capital Markets Operator Welcome to the LeMaitre Vascular Q2 2024 Financial Results Conference ...

LeMaitre Vascular (LMAT) came out with quarterly earnings of $0.52 per share, beating the Zacks Consensus Estimate of $0.47 per share. This compares to earnings of $0.37 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 10.64%. A quarter ago, it was expected that this medical device maker would post earnings of $0.39 per share when it actually produced earnings of $0.44, delivering a surprise of 12.82%. Over the last four quart ...

Exhibit 99.1 LeMaitre Q2 2024 Financial Results BURLINGTON, MA, August 1, 2024 - LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q2 2024 results, announced a $0.16/share quarterly dividend and provided guidance. Q2 2024 Financial Results ● Sales $55.8mm, +11% (+12% organic) vs. Q2 2023 ● Gross margin 68.9%, +490 bps ● Op. income $14.4mm, +52% ● Op. margin 26% ● Net income $11.8mm, +46% ● Earnings per diluted share $0.52, +44% ● Cash up $4.8mm sequentially to $11 ...

BURLINGTON, Mass., July 16, 2024 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its second quarter 2024 financial results on Thursday, August 1, 2024, after the market close. The company has scheduled a conference call for 5:00 PM ET the same day to discuss the results, business highlights, and company outlook. About LeMaitre LeMaitre is a provider of devices, implants, and services for the treatment of peripheral vascular disease, a condition that affects mor ...

About LeMaitre BURLINGTON, Mass., July 16, 2024 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its second quarter 2024 financial results on Thursday, August 1, 2024, after the market close. The company has scheduled a conference call for 5:00 PM ET the same day to discuss the results, business highlights, and company outlook. LeMaitre is a provider of devices, implants, and services for the treatment of peripheral vascular disease, a condition that affects mor ...

1 IF D H HT T 100 - 100 1 i T 1 Pgiam/iStock via Getty Images Following my last report on LeMaitre Vascular, Inc. (NASDAQ:LMAT) in August FY'23, shares have rallied another 45% into the green, along with 1) increased dividends and 2) improving fundamentals. Back then, I valued the stock at ~$85/share, roughly where it trades today. LMAT is a long-term compounder with mouth-watering economics in my view. Management's efforts have produced a 27% CAGR in market value and 18% CAGR in dividend growth since 2011 ...

Investors might want to bet on LeMaitre Vascular (LMAT) , as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices. Most Powerful Force Impacting Stock Prices As empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, tracking such revisions for making an investment decision could be truly rewarding. ...

BURLINGTON, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that George W. LeMaitre, Chairman & CEO, will present at the 2024 Jefferies Global Healthcare Conference on Thursday, June 6, 2024, at 11:00 AM ET at the Marriott Marquis in New York City. About LeMaitre LeMaitre is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufact ...